The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Viscosupplementation for the treatment of osteoarthritis of the knee
Open accessAbstract
BACKGROUND: Osteoarthritis (OA) is the most prevalent chronic joint disorder worldwide and is associated with significant pain and disability. OBJECTIVES: To assess the effects of viscosupplementation in the treatment of OA of the knee. The products were hyaluronan and hylan derivatives (Adant, Arthrum H, Artz (Artzal, Supartz), BioHy (Arthrease, Euflexxa, Nuflexxa), Durolane, Fermathron, Go-On, Hyalgan, Hylan G-F 20 (Synvisc Hylan G-F 20), Hyruan, NRD-101 (Suvenyl), Orthovisc, Ostenil, Replasyn, SLM-10, Suplasyn, Synject and Zeel compositum). SEARCH STRATEGY: MEDLINE (up to January (week 1) 2006 for update), EMBASE, PREMEDLINE, Current Contents up to July 2003, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched. Specialised journals and reference lists of identified randomised controlled trials (RCTs) and pertinent review articles up to December 2005 were handsearched. SELECTION CRITERIA: RCTs of viscosupplementation for the treatment of people with a diagnosis of OA of the knee were eligible. Single and double-blinded studies, placebo-based and comparative studies were eligible. At least one of the four OMERACT III core set outcome measures had to be reported (Bellamy 1997). DATA COLLECTION AND ANALYSIS: Each trial was assessed independently by two reviewers for its methodological quality using a validated tool. All data were extracted by one reviewer and verified by a second reviewer . Continuous outcome measures were analysed as weighted mean differences (WMD) with 95% confidence intervals (CI). However, where different scales were used to measure the same outcome, standardized mean differences (SMD) were used. Dichotomous outcomes were analyzed by relative risk (RR). MAIN RESULTS: Seventy-six trials with a median quality score of 3 (range 1 to 5) were identified. Follow-up periods varied between day of last injection and eighteen months. Forty trials included comparisons of hyaluronan/hylan and placebo (saline or arthrocentesis), ten trials included comparisons of intra-articular (IA) corticosteroids, six trials included comparisons of nonsteroidal anti-inflammatory drugs (NSAIDs), three trials included comparisons of physical therapy, two trials included comparisons of exercise, two trials included comparisons of arthroscopy, two trials included comparisons of conventional treatment, and fifteen trials included comparisons of other hyaluronans/hylan. The pooled analyses of the effects of viscosupplements against 'placebo' controls generally supported the efficacy of this class of intervention. In these same analyses, differential efficacy effects were observed for different products on different variables and at different timepoints. Of note is the 5 to 13 week post injection period which showed a percent improvement from baseline of 28 to 54% for pain and 9 to 32% for function. In general, comparable efficacy was noted against NSAIDs and longer-term benefits were noted in comparisons against IA corticosteroids. In general, few adverse events were reported in the hyaluronan/hylan trials included in these analyses. AUTHORS' CONCLUSIONS: Based on the aforementioned analyses, viscosupplementation is an effective treatment for OA of the knee with beneficial effects: on pain, function and patient global assessment; and at different post injection periods but especially at the 5 to 13 week post injection period. It is of note that the magnitude of the clinical effect, as expressed by the WMD and standardised mean difference (SMD) from the RevMan 4.2 output, is different for different products, comparisons, timepoints, variables and trial designs. However, there are few randomised head-to-head comparisons of different viscosupplements and readers should be cautious, therefore, in drawing conclusions regarding the relative value of different products. The clinical effect for some products, against placebo, on some variables at some timepoints is in the moderate to large effect-size range. Readers should refer to relevant tables to review specific detail given the heterogeneity in effects across the product class and some discrepancies observed between the RevMan 4.2 analyses and the original publications. Overall, the analyses performed are positive for the HA class and particularly positive for some products with respect to certain variables and timepoints, such as pain on weight bearing at 5 to 13 weeks postinjection. In general, sample-size restrictions preclude any definitive comment on the safety of the HA class of products; however, within the constraints of the trial designs employed no major safety issues were detected. In some analyses viscosupplements were comparable in efficacy to systemic forms of active intervention, with more local reactions but fewer systemic adverse events. In other analyses HA products had more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Altman, R., Asch, E., Bloch, D., Bole, G., Borenstein, D., Brandt, K., Christy, W., Cooke, T. D., Greenwald, R., Hochberg, M., et al. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290816 · Cited by 6,777
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Kushner (2021) · doi:10.12788/jfp · Cited by 3,799
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Analysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116
Cited by
Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.12.013 · Cited by 2,796
Osteoarthritis: an update with relevance for clinical practice
Bijlsma, J. W., Berenbaum, F., & Lafeber, F. P. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60243-2 · Cited by 2,288
OARSI recommendations for the management of hip and knee osteoarthritis
Zhang, W., Nuki, G., Moskowitz, R. W., Abramson, S., Altman, R. D., Arden, N. K., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.013 · Cited by 1,700
Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., Dinçer, F., Dziedzic, K., Häuselmann, H. J., Herrero-Beaumont, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062091 · Cited by 1,338
Felson, D. T. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp051726 · Cited by 986
Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review and Meta-analysis
Rutjes, A. W. S., Jüni, P., da Costa, B. R., Trelle, S., Nüesch, E., & Reichenbach, S. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-3-201208070-00473 · Cited by 717
Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.008 · Cited by 695
Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline, 2nd Edition
Jevsevar, D. S. (2013) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-201309020-00008 · Cited by 634
Bannuru, R. R., Schmid, C. H., Kent, D. M., Vaysbrot, E. E., Wong, J. B., & McAlindon, T. E. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1231 · Cited by 623
High and low molecular weight hyaluronic acid differentially influence macrophage activation
Rayahin, J. E., Buhrman, J. S., Zhang, Y., Koh, T. J., & Gemeinhart, R. A. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00181 · Cited by 605
Kon, E., Mandelbaum, B., Buda, R., Filardo, G., Delcogliano, M., Timoncini, A., Fornasari, P. M., Giannini, S., & Marcacci, M. (2011) · Arthroscopy: The Journal of Arthroscopic & Related Surgery · doi:10.1016/j.arthro.2011.05.011 · Cited by 582
Intra-articular treatment options for knee osteoarthritis
Jones, I. A., Togashi, R., Wilson, M. L., Heckmann, N., & Vangsness, C. T. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0123-4 · Cited by 525
Altman, R., Manjoo, A., Fierlinger, A., Niazi, F., & Nicholls, M. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0775-z · Cited by 486
Chondrocyte dedifferentiation and osteoarthritis (OA)
Charlier, E., Deroyer, C., Ciregia, F., Malaise, O., Neuville, S., Plener, Z., Malaise, M., & de Seny, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.02.036 · Cited by 460
Bannuru, R. R., Natov, N. S., Obadan, I. E., Price, L. L., Schmid, C. H., & McAlindon, T. E. (2009) · Arthritis Care & Research · doi:10.1002/art.24925 · Cited by 453
Osteoarthritis: Diagnosis and Treatment
(1961) · BMJ · doi:10.1136/bmj.1.5222.355-a · Cited by 452
Ayhan, E. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.351 · Cited by 441
Matas, J., Orrego, M., Amenabar, D., Infante, C., Tapia-Limonchi, R., Cadiz, M. I., Alcayaga-Miranda, F., González, P. L., Muse, E., Khoury, M., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0053 · Cited by 413
Görmeli, G., Görmeli, C. A., Ataoglu, B., Çolak, C., Aslantürk, O., & Ertem, K. (2017) · Knee Surgery, Sports Traumatology, Arthroscopy · doi:10.1007/s00167-015-3705-6 · Cited by 401
Bannuru, R. R., Natov, N. S., Dasi, U. R., Schmid, C. H., & McAlindon, T. E. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.09.014 · Cited by 388
Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis
Baltzer, A. W. A., Moser, C., Jansen, S. A., & Krauspe, R. (2009) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2008.06.014 · Cited by 317
Braces and orthoses for treating osteoarthritis of the knee
Duivenvoorden, T., Brouwer, R. W., van Raaij, T. M., Verhagen, A. P., Verhaar, J. A., & Bierma-Zeinstra, S. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004020.pub3 · Cited by 314
Duymus, T. M., Mutlu, S., Dernek, B., Komur, B., Aydogmus, S., & Kesiktas, F. N. (2017) · Knee Surgery, Sports Traumatology, Arthroscopy · doi:10.1007/s00167-016-4110-5 · Cited by 297
Recent advances in hyaluronic acid based therapy for osteoarthritis
Bowman, S., Awad, M. E., Hamrick, M. W., Hunter, M., & Fulzele, S. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0180-3 · Cited by 288
Viscosupplementation for Osteoarthritis of the Knee
Hunter, D. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmct1215534 · Cited by 287
Chevalier, X., Jerosch, J., Goupille, P., van Dijk, N., Luyten, F. P., Scott, D. L., Bailleul, F., & Pavelka, K. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094623 · Cited by 283
Qvistgaard, E., Christensen, R., Torp-Pedersen, S., & Bliddal, H. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2005.09.007 · Cited by 274
Bruyère, O., Cooper, C., Pelletier, J.-P., Maheu, E., Rannou, F., Branco, J., Luisa Brandi, M., Kanis, J. A., Altman, R. D., Hochberg, M. C., et al. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.11.010 · Cited by 274
Lu, L., Dai, C., Zhang, Z., Du, H., Li, S., Ye, P., Fu, Q., Zhang, L., Wu, X., Dong, Y., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1248-3 · Cited by 260
Chondroitin for osteoarthritis
Singh, J. A., Noorbaloochi, S., MacDonald, R., & Maxwell, L. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005614.pub2 · Cited by 260
Efficacy and Safety of Hylan versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis
Dai, W.-L., Lin, Z.-M., Guo, D.-H., Shi, Z.-J., & Wang, J. (2019) · The Journal of Knee Surgery · doi:10.1055/s-0038-1641142 · Cited by 24
Metadata
- Authors
- Bellamy, N., Campbell, J., Welch, V., Gee, T. L., Bourne, R., & Wells, G. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-04-19
- Volume
- 2014
- Issue
- 11
- Pages
- CD005321-CD005321
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2118238661
- Cited by
- 755
- References
- 116
- FWCI
- 27.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.